The pathological significance of this pathway was validated upon oncogenic KRAS expression in HEK239T cells and in the NSCLC cell line A549, which harbours an endogenous oncogenic KRASG12S mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.